Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine prophylaxis for osteopenia of prematurity in preterm infants
IRCT20230914059430N2Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of caffeine in osteopenia of prematurity (MBD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Premature osteopenia. Started Apr 2023; status: completed.
02
Drugs
caffeine
03
Conditions
osteopenia of prematurity (MBD)
Beyond the preview
Go deeper on IRCT20230914059430N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230914059430N2.